Pricing Log in Create free account

Lycia Therapeutics Inc. (LYCA) vs SELLAS Life Sciences Group, Inc. (SLS)

Lycia Therapeutics Inc. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Lycia Therapeutics Inc. and SELLAS Life Sciences Group, Inc. are of similar size ($1.7B and $1.6B).

Valuation

Metric LYCA SLS Biotechnology median
P/E — n/m 10.60
P/S — 149.37 9.40
P/B — 11.39 2.13
Price to free cash flow — n/m 25.18
EV/EBITDA — n/m 0.66
EV/Sales — 136.22 9.02
Earnings yield — (2.53%) (32.88%)
Free cash flow yield — (2.45%) (23.13%)

Profitability

Metric LYCA SLS Biotechnology median
Gross margin — 0.00% 68.51%
Operating margin — 0.00% 0.00%
Net margin — 0.00% 0.00%
Free cash flow margin — 0.00% 0.00%
Return on equity — (39.63%) (51.96%)
Return on assets — (36.54%) (46.06%)
Return on invested capital — 0.00% 0.00%

Growth

Metric LYCA SLS Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) — 50.00% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric LYCA SLS Biotechnology median
Debt to equity — 0.00 0.00
Current ratio — 18.83 4.97
Net debt to EBITDA — 2.54 1.01

Dividend

Metric LYCA SLS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LYCA SLS Biotechnology median
Market cap 1.66b 1.59b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack